ALK fusion: Gene Variant Detail - Cancer Knowledgebase (CKB)

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial	Phase	Therapies	Title	Recruitment Status	Covered Countries	Other Countries
NCT04083976	Phase II	Erdafitinib	A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations (RAGNAR)	Active, not recruiting	USA \| POL \| ITA \| GBR \| FRA \| ESP \| DEU \| BRA \| BEL \| AUS \| ARG	4
NCT03775486	Phase II	Durvalumab + Olaparib Cisplatin + Durvalumab + Pemetrexed Disodium Durvalumab Carboplatin + Durvalumab + Gemcitabine Carboplatin + Durvalumab + Pemetrexed Disodium Carboplatin + Durvalumab + Nab-paclitaxel Cisplatin + Durvalumab + Gemcitabine	Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION) (ORION)	Active, not recruiting	USA \| POL \| NLD \| HUN \| GBR \| BEL	6
NCT04612751	Phase I	Datopotamab deruxtecan + Durvalumab AZD2936 + Carboplatin + Datopotamab deruxtecan AZD2936 + Datopotamab deruxtecan Carboplatin + Datopotamab deruxtecan + Durvalumab Datopotamab deruxtecan + MEDI5752 Carboplatin + Datopotamab deruxtecan + MEDI5752	Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung04)	Active, not recruiting	USA \| TUR \| POL \| ITA \| ESP \| BEL	2
NCT04541407	Phase I	Osimertinib + Temozolomide Lorlatinib + Temozolomide	Temodar Plus Tyrosine Kinase Inhibitors for Progressive CNS Disease	Completed	USA	0
NCT05557591	Phase II	Cemiplimab BNT116 + Cemiplimab	A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)	Active, not recruiting	USA \| TUR \| ESP \| DEU	3
NCT06908993	Phase III	Vinorelbine Pemetrexed Disodium Tepotinib Pembrolizumab Bevacizumab + Paclitaxel Paclitaxel Docetaxel Nivolumab Atezolizumab Gemcitabine	Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated (COMET)	Recruiting	FRA	0
NCT06007937	Phase Ib/II	Lorlatinib + Ramucirumab	A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer	Recruiting	USA	0
NCT06465329	Phase II	Cemiplimab + REGN7075 REGN7075 Cemiplimab	A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)	Recruiting	USA \| TUR \| FRA \| ESP \| DEU \| BRA	0
NCT06726265	Phase III	Carboplatin + Paclitaxel + Pembrolizumab Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Eftilagimod alpha + Paclitaxel + Pembrolizumab Cisplatin + Eftilagimod alpha + Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Eftilagimod alpha + Pembrolizumab + Pemetrexed Disodium	Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)	Recruiting	TUR \| ROU \| POL \| LVA \| LTU \| ITA \| IRL \| HUN \| HRV \| GRC \| GBR \| ESP \| DEU \| CAN \| BGR \| BEL \| AUT \| AUS	5
NCT05742607	Phase II	Cisplatin + Durvalumab + IPH5201 + Pemetrexed Disodium Carboplatin + Durvalumab + IPH5201 + Pemetrexed Disodium Carboplatin + Durvalumab + IPH5201 + Paclitaxel	IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)	Recruiting	USA \| POL \| HUN \| GRC \| FRA	0
NCT05624996	Phase III	Cisplatin + Durvalumab + Etoposide Carboplatin + Durvalumab + Pemetrexed Disodium Cisplatin + Durvalumab + Pemetrexed Disodium Carboplatin + Durvalumab + Paclitaxel	Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-small Cell Lung Cancer	Recruiting	USA \| CAN	0
NCT04800822	Phase I	PF-07284892 Cetuximab + Encorafenib + PF-07284892 Lorlatinib + PF-07284892 Binimetinib + PF-07284892	PF-07284892 in Participants With Advanced Solid Tumors	Terminated	USA	0
NCT03915951	Phase II	Binimetinib + Encorafenib	An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer	Completed	USA \| NLD \| ITA \| ESP	1
NCT05241873	Phase Ib/II	BLU-451	(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations	Terminated	USA \| CAN	3
NCT03970746	Phase Ib/II	PDClung01 + Pembrolizumab PDClung01 + Pemetrexed Disodium PDC*lung01	Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC	Active, not recruiting	POL \| NLD \| FRA \| DEU \| BEL	0
NCT06917573	Phase II	Cemiplimab Carboplatin + Cemiplimab + Paclitaxel	PALACE: Cemiplimab Trial According to ctDNA Levels (PALACE)	Recruiting	ESP	0
NCT03057106	Phase II	Cisplatin Gemcitabine Carboplatin Durvalumab + Tremelimumab Pemetrexed Disodium	Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC	Active, not recruiting	CAN \| AUS	0
NCT04956692	Phase III	Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab	Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)	Active, not recruiting	USA \| TUR \| ROU \| POL \| HUN \| FRA \| ESP \| BRA	8
NCT05882734	Phase Ib/II	Cemiplimab + M1774	Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)	Active, not recruiting	USA \| ITA \| FRA \| ESP \| DEU \| BEL	2
NCT04931654	Phase Ib/II	AZD7789	A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer	Active, not recruiting	USA \| TUR \| NLD \| FRA \| ESP \| CAN	4
NCT04862780	Phase Ib/II	BLU-945 BLU-945 + Osimertinib	(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC	Terminated	USA \| NLD \| GBR \| FRA \| ESP \| CAN	4
NCT06532032	Phase Ib/II	Amivantamab-vmjw + Docetaxel	A Study of Combination Therapy With Amivantamab and Docetaxel in Participants With Metastatic Non-small Cell Lung Cancer (swalloWTail)	Active, not recruiting	USA \| TUR \| GBR	1
NCT05650203	Phase I	JS006 + JS009 + Toripalimab-tpzi JS009	A Study of JS009 Monotherapy and JS009 as a Triple Combination Therapy in Patients With Advanced Malignancies	Withdrawn		0
NCT06008093	Phase III	Cisplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Durvalumab + Pemetrexed Disodium + Tremelimumab Carboplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Durvalumab + Pemetrexed Disodium + Tremelimumab	A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients (TRITON)	Recruiting	USA	0
NCT06333899	Phase I	Lorlatinib Cisplatin + Cyclophosphamide + Lorlatinib + Vincristine Sulfate Carboplatin + Cyclophosphamide + Etoposide + Lorlatinib + Methotrexate + Vincristine Sulfate	Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion	Active, not recruiting	USA \| NLD \| DEU \| CAN \| AUS	0
NCT06564844	Phase III	Tegafur-gimeracil-oteracil Potassium Etoposide AZD2936 + Datopotamab deruxtecan Carboplatin AZD2936 Vinorelbine Pemetrexed Disodium Cisplatin	A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features (TROPION-Lung12)	Recruiting	USA \| TUR \| SWE \| POL \| NLD \| ITA \| HUN \| GBR \| FRA \| ESP \| DEU \| CHE \| CAN \| BRA \| BEL \| AUS	7
NCT04832854	Phase II	Atezolizumab + Carboplatin + Pemetrexed Disodium + Tiragolumab Atezolizumab + Carboplatin + Paclitaxel + Tiragolumab Atezolizumab + Tiragolumab Atezolizumab + Cisplatin + Pemetrexed Disodium + Tiragolumab Atezolizumab + Carboplatin + Gemcitabine + Tiragolumab Atezolizumab + Cisplatin + Gemcitabine + Tiragolumab Cisplatin + Gemcitabine Carboplatin + Gemcitabine Carboplatin + Paclitaxel Carboplatin + Pemetrexed Disodium Cisplatin + Pemetrexed Disodium	A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer	Completed	USA \| ESP \| CHE \| AUS	1
NCT05048797	Phase III	Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Trastuzumab deruxtecan	A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations	Recruiting	USA \| TUR \| POL \| NLD \| ITA \| FRA \| ESP \| DNK \| DEU \| CAN \| BRA \| BEL \| AUT	7
NCT05501665	Phase Ib/II	Carboplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Nab-paclitaxel + Pembrolizumab	Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer	Recruiting	USA	0
NCT06116682	Phase II	Amivantamab-vmjw	Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)	Recruiting	USA	0
NCT05775289	Phase II	Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Paclitaxel + RO7247669 Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Pemetrexed Disodium + RO7247669 Carboplatin + Pemetrexed Disodium + RO7247669 RO7247669	A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer	Active, not recruiting	USA \| TUR \| ITA \| FRA \| ESP \| DEU \| BRA \| BEL \| AUS	2
NCT06225427	Phase I	Gilteritinib	Gilteritinib for the Treatment of ALK NSCLC	Recruiting	USA	0
NCT05383001	Phase II	Cisplatin + Vinorelbine Carboplatin + Vinorelbine Cisplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium Carboplatin + Paclitaxel Cisplatin + Paclitaxel Cisplatin + Nab-paclitaxel Durvalumab + Tremelimumab Carboplatin + Nab-paclitaxel Cisplatin + Gemcitabine Carboplatin + Gemcitabine	Randomized Phase II, Open-label Efficacy and Safety Study of Second-line Durvalumab Plus Tremelimumab Versus Platinum-based Chemotherapy Alone in Patients With NSCLC and First-line Checkpoint-inhibitor Therapy (Re-Check)	Withdrawn	DEU	0
NCT05005273	Phase II	Ipilimumab + Nivolumab BMS-986207 + Ipilimumab + Nivolumab	A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer	Completed	USA \| TUR \| POL \| ITA \| ISR \| FRA \| ESP \| DEU \| BEL \| AUS \| ARG	1
NCT05170204	Phase III	Durvalumab Alectinib	A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC) (HORIZON 1)	Recruiting	USA \| TUR \| SWE \| POL \| NZL \| NOR \| NLD \| ITA \| ISR \| GBR \| FRA \| ESP \| DEU \| CAN \| BRA \| BEL \| AUS	13
NCT05709821	Phase Ib/II	Pembrolizumab IMM60 IMM60 + Pembrolizumab	IMM60 and Pembrolizumab in Melanoma and NSCLC	Terminated	USA \| GBR \| ESP	0
NCT04484142	Phase II	Datopotamab deruxtecan	Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05)	Active, not recruiting	USA \| NLD \| ITA \| HUN \| FRA \| ESP \| DEU	3
NCT03334617	Phase II	Danvatirsen + Durvalumab Durvalumab + Olaparib Cediranib + Durvalumab Ceralasertib Durvalumab + Vistusertib Durvalumab + Trastuzumab deruxtecan Ceralasertib + Durvalumab Durvalumab + Oleclumab	Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy (HUDSON)	Active, not recruiting	USA \| ISR \| FRA \| ESP \| DEU \| CAN \| AUT	1
NCT03906071	Phase III	Docetaxel Nivolumab + Sitravatinib	Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer (SAPPHIRE)	Completed	USA \| NLD \| ITA \| ISR \| HUN \| GBR \| FRA \| ESP \| DEU \| CHE \| CAN \| BEL	0
NCT04644315	Phase II	Alectinib	A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors (ALpha-T)	Terminated	USA	0
NCT05014815	Phase II	BGBA1217 + Tislelizumab Tislelizumab	Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer	Completed	USA \| GRC \| FRA \| ESP \| AUT \| AUS	2
NCT02657434	Phase III	Cisplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium Atezolizumab + Carboplatin + Pemetrexed Disodium Atezolizumab + Cisplatin + Pemetrexed Disodium	A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132)	Completed	USA \| ROU \| NLD \| LVA \| LTU \| ITA \| ISR \| IRL \| HUN \| GBR \| FRA \| ESP \| BGR \| BEL \| AUT \| AUS \| ARG	10
NCT05788926	Phase I	TG6050	A Clinical Trial of TG6050 in Patients With Metastatic Non-Small Cell Lung Cancer (Delivir)	Terminated	FRA	0
NCT06865339	Phase II	Cemiplimab + Fianlimab	Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer (TRIPL)	Recruiting	USA	0
NCT04923126	Phase Ib/II	Mirdametinib	SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma	Recruiting	USA	0
NCT05718297	Phase II	Brigatinib Durvalumab	Brigatinib Post Definitive Chemo-radiotherapy in Patients With ALK-fusion Non-small Cell Lung Cancer (BOUNCE)	Withdrawn	POL \| ITA \| GBR \| FRA \| ESP	0
NCT03166631	Phase I	BI 891065 + Ezabenlimab BI 891065	A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread	Terminated	USA	0
NCT03255083	Phase I	DS-1205c + Osimertinib	DS-1205c With Osimertinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer	Terminated		1
NCT04892953	Phase II	Carboplatin + Durvalumab + Paclitaxel Carboplatin + Durvalumab + Nab-paclitaxel Carboplatin + Durvalumab + Gemcitabine Durvalumab	Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy	Recruiting	USA	0
NCT04929041	Phase II	Ipilimumab + Nivolumab	Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative	Recruiting	USA	0
NCT04644237	Phase II	Trastuzumab deruxtecan	Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC) (DESTINY-LUNG02)	Completed	USA \| NLD \| ITA \| FRA \| ESP \| CAN \| AUS	3
NCT05840770	Phase II	Cemiplimab	Cemiplimab for the Treatment of Untreated Brain Metastases From PD-L1 >= 50% Non-Small Cell Lung Cancer	Withdrawn		0
NCT07017829	Phase II	GT103 + Pembrolizumab	GT103 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic STK11 Mutant Non-Small Cell Lung Cancer	Recruiting	USA	0
NCT04746924	Phase III	Tislelizumab BGBA1217 + Tislelizumab Pembrolizumab	A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer	Active, not recruiting	USA \| TUR \| POL \| NLD \| ITA \| FRA \| ESP \| DEU \| BRA \| AUS \| ARG	8
NCT05077709	Phase II	IO102-IO103 + Pembrolizumab	IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC	Active, not recruiting	USA \| GBR \| ESP	0
NCT04655976	Phase II	Docetaxel Cobolimab + Docetaxel + Dostarlimab-gxly Docetaxel + Dostarlimab-gxly	Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-Small Cell Lung Cancer Who Have Progressed on Prior Anti- Programmed Death-ligand 1 (PD-[L]1) Therapy and Chemotherapy (COSTAR Lung)	Active, not recruiting	USA \| TUR \| SWE \| ROU \| POL \| NLD \| ITA \| GRC \| GBR \| FRA \| FIN \| ESP \| DEU \| CAN \| BRA \| BEL \| AUS \| ARG	6
NCT06162572	Phase Ib/II	Cemiplimab + S095029 Cemiplimab + Sym024 Cemiplimab + Sym023 Cemiplimab	Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)	Recruiting	USA \| ROU \| ITA \| HUN \| GBR \| FRA \| ESP \| BRA \| BEL \| AUT \| AUS \| ARG	3
NCT05417321	Phase Ib/II	HB0036	A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors	Recruiting	USA	1
NCT06498635	Phase III	Durvalumab	Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial	Recruiting	USA	0
NCT05153408	Phase Ib/II	BLU-701 BLU-701 + Osimertinib BLU-701 + Carboplatin + Pemetrexed Disodium	(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC	Terminated	USA	0
NCT05785767	Phase II	Cemiplimab Cemiplimab + Fianlimab	A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)	Recruiting	USA \| TUR \| ISR \| ESP \| CAN \| AUS	5
NCT05800015	Phase II	Cemiplimab + Cisplatin + Fianlimab + Pemetrexed Disodium Carboplatin + Cemiplimab + Fianlimab + Paclitaxel Cemiplimab + Cisplatin + Paclitaxel Carboplatin + Cemiplimab + Paclitaxel	A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer	Recruiting	USA \| TUR \| ISR \| CAN \| AUS	5
NCT06275360	Phase II	Nivolumab Carboplatin + Nivolumab + Pemetrexed Disodium Carboplatin + Nivolumab + Paclitaxel	Repositioning Immunotherapy in VetArans With Lung Cancer (RIVAL)	Recruiting	USA	0
NCT04863248	Phase II	Docetaxel + Trilaciclib Docetaxel	Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Docetaxel for Metastatic Non-Small Cell Lung Cancer (NSCLC) (PRESERVE 4)	Terminated	USA	0
NCT02097810	Phase I	Entrectinib	Study of Oral RXDX-101 in Adult Patients With Locally Advanced or Metastatic Cancer Targeting NTRK1, NTRK2, NTRK3, ROS1, or ALK Molecular Alterations. (STARTRK-1)	Completed	USA	1
NCT04940637	Phase II	Dostarlimab-gxly + Niraparib	UNITO-001- Study in HRR/PDL1 Positive MPM/NSCLC (UNITO-001)	Unknown status	ITA	0
NCT05061550	Phase II	Durvalumab + Monalizumab Datopotamab deruxtecan + Durvalumab AZD0171 + Durvalumab Durvalumab + Oleclumab AZD2936 AZD2936 + Datopotamab deruxtecan MEDI5752	Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer (NeoCOAST-2)	Recruiting	USA \| TUR \| ITA \| IRL \| HUN \| FRA \| ESP \| CAN \| BEL	3
NCT06364917	Phase II	Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab + Pemetrexed Disodium Ipilimumab + Nivolumab Carboplatin + Ipilimumab + Nivolumab + Paclitaxel Carboplatin + Ipilimumab + Nivolumab + Pemetrexed Disodium Carboplatin + Paclitaxel + Pembrolizumab	DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC	Recruiting	USA	0
NCT04047862	Phase I	BGBA1217 + Tislelizumab BGBA1217 + Cisplatin + Pemetrexed Disodium + Tislelizumab BGBA1217 + Carboplatin + Pemetrexed Disodium + Tislelizumab BGBA1217 + Cisplatin + Paclitaxel + Tislelizumab BGBA1217 + Carboplatin + Paclitaxel + Tislelizumab BGBA1217 + Carboplatin + Nab-paclitaxel + Tislelizumab BGBA1217 + Capecitabine + Tislelizumab BGBA1217 + Cisplatin + Etoposide + Tislelizumab BGBA1217 + Cisplatin + Fluorouracil + Tislelizumab BGBA1217 + Carboplatin + Etoposide + Tislelizumab BGBA1217 + Capecitabine + Oxaliplatin + Tislelizumab	Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors	Completed	USA \| NZL \| AUS	3
NCT04116541	Phase II	Alectinib Dabrafenib + Trametinib Cabozantinib Avapritinib	A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors. (MegaMOST)	Recruiting	FRA	0
NCT04619797	Phase II	Atezolizumab + Pemetrexed Disodium + Tiragolumab Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium Atezolizumab + Carboplatin + Pemetrexed Disodium + Tiragolumab Atezolizumab + Cisplatin + Pemetrexed Disodium + Tiragolumab	A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer (SKYSCRAPER-06)	Active, not recruiting	USA \| TUR \| POL \| NZL \| ITA \| GBR \| FRA \| ESP \| DNK \| DEU \| CHE \| CAN \| BRA \| BEL	7
NCT03639714	Phase Ib/II	GRT-C901 + GRT-R902 + Ipilimumab + Nivolumab	A Study of a Personalized Neoantigen Cancer Vaccine	Completed	USA \| AUS	0
NCT02587650	Phase II	Ceritinib Capmatinib Regorafenib Entrectinib	Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma	Terminated	USA	0
NCT04776447	Phase II	Atezolizumab + Carboplatin + Paclitaxel	Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO) (APOLO)	Active, not recruiting	ESP	0
NCT05397171	Phase Ib/II	AZD8853	A First-in-human Study to Evaluate the Safety and Tolerability of AZD8853 in Participants With Selected Advanced/Metastatic Solid Tumours	Terminated	USA \| CAN	0
NCT04758949	Phase II	Nivolumab FL-101 + Nivolumab FL-101	FL-101 in Surgically Resectable Non-Small Cell Lung Cancer	Withdrawn		0
NCT04005144	Phase I	Binimetinib + Brigatinib	Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer	Terminated	USA	0
NCT04585815	Phase Ib/II	Axitinib + PF-06801591 + SGN-TGT Binimetinib + Encorafenib + PF-06801591	Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)	Terminated	USA \| GBR \| BEL \| AUS	1
NCT05845671	Phase Ib/II	Amivantamab-vmjw	Amivantamab With Tyrosine Kinase Inhibitors (TKI) for Advanced NSCLC With ALK, ROS1, or RET Alterations	Recruiting	USA	0
NCT06083857	Phase Ib/II	Amivantamab-vmjw + Tepotinib	PhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung Cancer	Active, not recruiting	USA	0
NCT06267001	Phase III	Atezolizumab Atezolizumab + Tiragolumab	A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy (SKYSCRAPER-15)	Active, not recruiting	TUR \| POL \| ITA \| BRA \| AUS \| ARG	5
NCT02650401	Phase I	Entrectinib	Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options (STARTRK-NG)	Active, not recruiting	USA \| ITA \| GBR \| FRA \| ESP \| DEU \| CAN	2
NCT03391869	Phase III	Ipilimumab + Nivolumab	Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer	Active, not recruiting	USA	0
NCT04589845	Phase II	Alectinib Divarasib Entrectinib RP-3500	Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study	Recruiting	USA \| POL \| NZL \| ITA \| ISR \| GBR \| FRA \| ESP \| DNK \| DEU \| CHE \| CAN \| BRA \| BEL \| AUS	9
NCT02949843	Phase II	Nivolumab + Pembrolizumab	Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations	Terminated	USA	0
NCT04526782	Phase II	Docetaxel Binimetinib + Encorafenib	ENCOrafenib with Binimetinib in BRAF NSCLC (ENCO-BRAF)	Active, not recruiting	FRA	0
NCT04267237	Phase II	Atezolizumab + Autogene cevumeran Atezolizumab	A Study of the Efficacy and Safety of RO7198457 in Combination With Atezolizumab Versus Atezolizumab Alone Following Adjuvant Platinum-Doublet Chemotherapy in Participants Who Are ctDNA Positive After Surgical Resection of Stage II-III Non-Small Cell Lung Cancer	Withdrawn		0
NCT05671510	Phase III	ONC-392 Docetaxel	ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors (PRESERVE-003)	Recruiting	USA \| TUR \| NLD \| ITA \| GBR \| ESP \| DEU \| CAN \| BEL \| AUS	2
NCT04725188	Phase II	Docetaxel Docetaxel + MK-7684A MK-7684A	Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002, KEYVIBE-002)	Completed	USA \| POL \| ITA \| ISR \| FRA \| FIN \| ESP \| DNK \| DEU \| CHE \| BRA \| BEL \| AUT \| AUS \| ARG	5
NCT04581824	Phase II	Carboplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Dostarlimab-gxly + Pemetrexed Disodium Carboplatin + Dostarlimab-gxly + Pemetrexed Disodium	Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)	Terminated	USA \| ROU \| POL \| ITA \| FRA \| ESP \| DEU \| BRA \| ARG	3
NCT05746481	Phase II	Atezolizumab + Carboplatin + Pemetrexed Disodium + Tiragolumab	Carboplatin, Pemetrexed, and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases	Active, not recruiting	USA	0
NCT05171777	Phase II	Atezolizumab	A Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared With Intravenous Atezolizumab Formulation in Participants With Non-Small Cell Lung Cancer	Completed	USA \| POL \| LVA \| ITA \| FIN \| ESP \| CAN \| BRA \| ARG	3
NCT02134886	Phase I	Erlotinib	Erlotinib Hydrochloride in Treating Non-Small Cell Lung Cancer That is Metastatic or Cannot be Removed by Surgery in Patients With HIV Infection	Terminated	USA	0
NCT05015010	Phase II	Alectinib	Alectinib in Neo-adjuvant Treatment of Stage III NSCLC (ALNEO)	Active, not recruiting	ITA	0
NCT05364645	Phase II	Carboplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium + Selpercatinib	Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung Cancer	Withdrawn	USA	0
NCT04895579	Phase I	Copanlisib + Durvalumab	Lung Cancer With Copanlisib and Durvalumab (LCD)	Completed	USA	0
NCT02314481	Phase II	Vemurafenib Atezolizumab + Carboplatin + Paclitaxel Atezolizumab + Carboplatin + Pemetrexed Disodium Atezolizumab + Cisplatin + Pemetrexed Disodium Atezolizumab Alectinib Ado-trastuzumab emtansine	Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity (DARWINII)	Active, not recruiting	GBR	0
NCT04085315	Phase I	Alisertib + Osimertinib	Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer	Recruiting	USA	0
NCT07154706	Phase III	Taletrectinib	Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)	Recruiting	USA	0
NCT03868423	Phase II	Brigatinib	Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers	Withdrawn	USA	0
NCT05379595	Phase Ib/II	Amivantamab-vmjw Amivantamab-vmjw + Fluorouracil + Irinotecan + Leucovorin Amivantamab-vmjw + Fluorouracil + Leucovorin + Oxaliplatin	A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer (OrigAMI-1)	Recruiting	USA \| ITA \| ESP \| DEU \| CAN \| BEL	5
NCT04856176	Phase II	Carboplatin + Paclitaxel + Pembrolizumab + Sargramostim Carboplatin + Paclitaxel + Pembrolizumab + Pemetrexed Disodium + Sargramostim	A Study of Sargramostim Plus Pembrolizumab With or Without Pemetrexed in Patients With Advance Non-small Cell Lung Cancer After Completion of Chemoimmunotherapy	Terminated	USA	0
NCT04925609	Phase Ib/II	Brigatinib	Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors (Briga-PED)	Recruiting	NLD \| FRA	0
NCT06623656	Phase II	Cemiplimab	Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC	Recruiting	USA	0
NCT06067776	Phase I	Cetuximab + Osimertinib + Tucatinib	Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell Cancer	Not yet recruiting	USA	0
NCT05825625	Phase II	Atezolizumab + Tiragolumab	NeoTRACK - Dissection of IO Efficacy in NSCLC by Longitudinal tracKing	Active, not recruiting	DEU	0
NCT04471428	Phase III	Docetaxel Atezolizumab + Cabozantinib	Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy (CONTACT-01)	Completed	USA \| POL \| ITA \| GRC \| GBR \| FRA \| ESP \| DEU \| BEL \| AUT \| AUS	4
NCT04793815	FDA approved	Pembrolizumab	Lung Cancer Cryo-Activation as a Novel Approach to Augment Immunotherapy Efficacy (CRYOVATE)	Completed	CAN	0
NCT04260802	Phase Ib/II	Avelumab + OC-001 OC-001	A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers	Recruiting	CAN	0
NCT03965468	Phase II	Carboplatin + Durvalumab + Paclitaxel + Tremelimumab	Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC (CHESS)	Recruiting	NLD \| ITA \| ESP \| CHE	0
NCT04736173	Phase II	Zimberelimab Carboplatin + Paclitaxel + Pemetrexed Disodium AB154 + Zimberelimab Pembrolizumab	Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer (ARC-10)	Active, not recruiting	USA \| TUR \| GRC	9
NCT03999710	Phase II	Durvalumab	Determining Whether Durvalumab in Combination With Radiation Therapy Can Prevent the Progression of Non-Small Cell Lung Cancer	Active, not recruiting	USA	0
NCT06996782	Phase Ib/II	AZD2936 + Cisplatin + Pemetrexed Disodium AZD2936 + Carboplatin + Pemetrexed Disodium AZD2936 + Cisplatin + Pemetrexed Disodium + Ramucirumab AZD2936 + Carboplatin + Paclitaxel AZD2936 + Carboplatin + Nab-paclitaxel + Ramucirumab AZD2936 + Carboplatin + Nab-paclitaxel AZD2936 + Pemetrexed Disodium AZD2936 + Carboplatin + Pemetrexed Disodium + Ramucirumab AB248 + AZD2936 AZD2936 + Carboplatin + Paclitaxel + Ramucirumab	A Platform Study in Non-Small Cell Lung Cancer (NSCLC) (ALTAIR)	Not yet recruiting	USA \| TUR \| POL \| NLD \| ITA \| FRA \| ESP \| BRA \| BEL	10
NCT04774718	Phase Ib/II	Alectinib	A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors	Recruiting	USA \| ITA \| GBR \| FRA \| ESP \| DNK \| DEU \| CAN \| BRA \| AUS	2
NCT04984811	Phase II	Atezolizumab + NT-I7	NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC	Active, not recruiting	USA	0
NCT03420508	Phase II	Ensartinib	Treating Patients With Melanoma and ALK Alterations With Ensartinib	Active, not recruiting	USA	0
NCT06448572	Phase Ib/II	EXL01 + Nivolumab	EXL01 in Combination With Nivolumab for Advanced NSCLC Refractory to Immunotherapy. (EXLIBRIS)	Recruiting	FRA	0
NCT06918132	Phase II	Cemiplimab + Fianlimab	Cemiplimab and Fianlimab Before Surgery for the Treatment of Stage IB-IIIB Non-Small Cell Lung Cancer (N-PLANC)	Recruiting	USA	0
NCT05798663	Phase II	Atezolizumab Atezolizumab + Tiragolumab	Atezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unresectable Stage III NSCLC	Active, not recruiting	USA	0
NCT04591431	Phase II	Everolimus Nivolumab Itacitinib Erlotinib Ponatinib Pemigatinib Ipatasertib Ipilimumab Cobimetinib Atezolizumab Palbociclib Entrectinib Vemurafenib Lapatinib Trastuzumab Brigatinib Alectinib Ado-trastuzumab emtansine Pertuzumab Vismodegib	The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy (ROME)	Unknown status	ITA	0
NCT03037385	Phase Ib/II	Pralsetinib	Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors (ARROW)	Completed	USA \| NLD \| ITA \| GBR \| FRA \| ESP \| DEU \| BEL	5
NCT04512430	Phase II	Atezolizumab + Bevacizumab + Carboplatin + Pemetrexed Disodium	Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients	Terminated	ESP	0
NCT03213652	Phase II	Ensartinib	Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)	Active, not recruiting	USA \| CAN \| AUS	1
NCT03164616	Phase III	Durvalumab + Tremelimumab Cisplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium Cisplatin + Gemcitabine Carboplatin + Gemcitabine Durvalumab Carboplatin + Nab-paclitaxel	Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON). (POSEIDON)	Active, not recruiting	USA \| POL \| HUN \| GBR \| DEU \| BRA \| BGR	12
NCT05781308	Phase II	Atezolizumab + Bevacizumab + Paclitaxel Bevacizumab + Paclitaxel	Combination of Paclitaxel-bevacizumab ± Atezolizumab in Patients With Advanced NSCLC Progressing After Immunotherapy & Chemotherapy (ADAPTABLE)	Active, not recruiting	FRA	0
NCT06495125	Phase II	Defactinib + Nivolumab + RO5126766	Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer	Recruiting	USA	0
NCT05757492	Phase Ib/II	CHS-006 + Toripalimab-tpzi	Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors	Terminated	USA	0
NCT06031688	Phase II	Tepotinib Ramucirumab + Tepotinib	Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)	Recruiting	USA	0
NCT00932451	Phase II	Crizotinib	An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene	Completed	USA \| SWE \| POL \| NLD \| ITA \| IRL \| HUN \| GRC \| GBR \| FRA \| ESP \| DEU \| CAN \| BRA \| BGR \| AUS	6
NCT05435846	Phase I	Capmatinib + Trametinib	Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skipping Mutation	Terminated	USA	0
NCT07153445	Phase II	Atezolizumab + Carboplatin + Paclitaxel	Neoadjuvant Treatment With Atezolizumab and Atezolizumab as Maintenance for the Treatment of Stage III Non Small-Cell Lung Cancer (NSCLC) (ATHENEA)	Recruiting	ESP	0
NCT05676749	Phase I	Aldesleukin + C-TIL051 + Pembrolizumab	C-TIL051 in Non-Small Cell Lung Cancer	Recruiting	USA	0
NCT03755102	Phase I	Dacomitinib	A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progression on Osimertinib.	Completed	USA	0
NCT06094296	Phase II	Cisplatin + Nivolumab + Pemetrexed Disodium BMS-986315 + Cisplatin + Nivolumab + Pemetrexed Disodium BMS-986315 + Carboplatin + Nivolumab + Pemetrexed Disodium BMS-986315 + Carboplatin + Nivolumab + Paclitaxel Carboplatin + Nivolumab + Pemetrexed Disodium Carboplatin + Nivolumab + Paclitaxel	A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)	Terminated	USA \| AUS	0
NCT03827850	Phase II	Erdafitinib	FGFR Inhibitor in FGFR Dysregulated Cancer (FIND)	Terminated	DEU	0
NCT03107988	Phase I	Cyclophosphamide + Lorlatinib + Topotecan Lorlatinib	NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)	Completed	USA \| GBR \| FRA \| CAN	0
NCT05064280	Phase II	Lenvatinib + Pembrolizumab	Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases	Recruiting	USA	0
NCT05012254	Phase II	Ipilimumab + Nivolumab Carboplatin + Ipilimumab + Nivolumab + Paclitaxel Cisplatin + Ipilimumab + Nivolumab + Pemetrexed Disodium Carboplatin + Ipilimumab + Nivolumab + Pemetrexed Disodium	Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain Metastases (NIVIPI-Brain)	Active, not recruiting	ESP	0
NCT05589818	Phase II	Pembrolizumab	Pembrolizumab for Advanced NSCLC and PS 2-3	Recruiting	USA	0
NCT06624059	Phase II	Alectinib + Cisplatin + Pemetrexed Disodium Alectinib + Carboplatin + Pemetrexed Disodium	A Study to See How Well and How Safely Different Treatments Work in a Group of Participants With Non-Small Cell Lung Cancer (NSCLC) (HORIZON 2)	Active, not recruiting	USA \| NZL \| ITA \| FRA \| ESP \| BRA \| AUS	5
NCT06625775	Phase I	BBO-10203 + Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin BBO-10203 + Trastuzumab BBO-10203 + Fulvestrant + Ribociclib BBO-10203	Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors	Recruiting	USA \| ESP \| AUS	0
NCT06758401	Phase III	Pembrolizumab Pembrolizumab + SGN-B6A	This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1. (Be6A Lung-02)	Recruiting	USA \| SVK \| POL \| NLD \| ITA \| ISR \| GRC \| FRA \| ESP \| DEU \| CZE \| BGR \| BEL \| AUS \| ARG	4
NCT04467801	Phase II	Ipatasertib Docetaxel + Ipatasertib	Ipatasertib and Docetaxel in Metastatic NSCLC Patients Who Have Failed 1st Line Immunotherapy (Ipat-Lung)	Unknown status	USA	0
NCT05816252	Phase II	Osimertinib + SKB264 Carboplatin + SKB264 Carboplatin + Pembrolizumab + SKB264 Pembrolizumab + SKB264 SKB264	A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-003)	Active, not recruiting	TUR \| ROU \| ESP	3
NCT05715229	Phase II	Carboplatin + Paclitaxel Carboplatin + Pemetrexed Disodium Ipilimumab + Nivolumab	Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy (G360-IIT)	Recruiting	USA	0
NCT04827576	Phase II	Docetaxel + Magrolimab	Study of Magrolimab in Patients With Solid Tumors (ELEVATELung&UC)	Terminated	USA \| POL \| GBR \| FRA \| ESP	0
NCT05401786	Phase II	Cemiplimab Ipilimumab	Anti-PD-1 Re-challenge After Immune Priming by Ipilimumab and Immune Boosting by Radiotherapy in Advanced NSCLC (RAD-IO)	Recruiting	NLD	0
NCT04294810	Phase III	Atezolizumab Atezolizumab + Tiragolumab	A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer (SKYSCRAPER-01)	Active, not recruiting	USA \| TUR \| POL \| NLD \| ITA \| HUN \| GRC \| ESP \| DEU \| CHE \| BRA \| AUT \| AUS	10
NCT06644768	Phase Ib/II	Pembrolizumab DS-3201b + Pembrolizumab	A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations	Recruiting	USA \| BRA \| ARG	3
NCT03191786	Phase III	Atezolizumab Gemcitabine Vinorelbine	A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet Chemotherapy (IPSOS)	Completed	SVK \| ROU \| POL \| LUX \| ITA \| IRL \| GBR \| ESP \| DNK \| DEU \| CZE \| CHE \| CAN \| BRA \| BGR \| BEL \| ARG	7
NCT03066661	Expanded access	Entrectinib	Expanded Access to Entrectinib for Cancers With NTRK1/2/3, ROS1, or ALK Gene Fusions	No longer available	USA	0
NCT03993873	Phase Ib/II	Elzovantinib	Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET (SHIELD-1)	Active, not recruiting	USA \| FRA \| ESP	2
NCT07020065	Phase II	Carboplatin + Cemiplimab + Gemcitabine Carboplatin + Cemiplimab + Pemetrexed Disodium Cemiplimab Carboplatin + Cemiplimab + Paclitaxel	Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50%	Not yet recruiting	CHE	0
NCT05493566	Phase I	Aldesleukin + Pembrolizumab	Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung Cancer	Recruiting	USA	0
NCT04108026	Phase II	Durvalumab	Immunotherapy in Patient with Poor General Condition (SAVIMMUNE)	Completed	FRA	0
NCT04513925	Phase III	Atezolizumab + Tiragolumab Durvalumab	A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) (SKYSCRAPER-03)	Completed	USA \| TUR \| POL \| NZL \| NLD \| ITA \| ISR \| HUN \| GRC \| GBR \| FRA \| ESP \| DEU \| CAN \| BRA \| BEL \| AUT \| AUS \| ARG	7
NCT03563716	Phase II	Atezolizumab + Tiragolumab Atezolizumab	A Study of Tiragolumab in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer	Active, not recruiting	USA \| FRA \| ESP	3
NCT00939770	Phase Ib/II	Crizotinib	Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma	Completed	USA \| CAN	0
NCT03155620	Phase II	Tazemetostat Tipifarnib Larotrectinib LY3023414 Vemurafenib Selpercatinib Palbociclib Olaparib Ulixertinib Erdafitinib Selumetinib Ensartinib	Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)	Active, not recruiting	USA \| CAN \| AUS	1
NCT03904108	Phase II	Ramucirumab	Platinum-Based Chemotherapy Plus Ramucirumab in Patients With Advanced NSCLC Who Have Progressed on First Line Anti-PD-1 Immunotherapy	Terminated	USA	0
NCT04268550	Phase II	Selpercatinib	Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial)	Active, not recruiting	USA	0
NCT02154490	Phase II	Docetaxel Nivolumab Palbociclib Durvalumab Ipilimumab + Nivolumab Fexagratinib Taselisib Durvalumab + Tremelimumab Erlotinib + Rilotumumab Talazoparib Erlotinib	Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer	Completed	USA \| CAN	0

Gene	ALK
Variant	fusion
Impact List	fusion
Protein Effect	unknown
Gene Variant Descriptions	ALK fusion indicates a fusion of the ALK gene, but the fusion partner is unknown.
Associated Drug Resistance
Category Variants Paths	ALK mutant ALK rearrange ALK fusion

ALK fusion
Gene Variant Detail

Contact

Filtering

Sorting

Filtering

Sorting

ALK fusionGene Variant Detail

Contact

Filtering

Sorting

Filtering

Sorting

ALK fusion
Gene Variant Detail